NCT06317064View on ClinicalTrials.gov

Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea

PHASE3CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 15, 2024

Primary Completion Date

October 31, 2024

Study Completion Date

December 15, 2024

Conditions

Primary Dysmenorrhea

Interventions

DRUG

Ibuprofen and Aprepitant

"All 30 participants in this group used NSAIDs (Non-steroidal Anti-Inflammatory Drugs), during their dysmenorrhea period. Same patients from phase 2 (n=30) in next cycle received NK1R antagonist Dexamethasone (6mg) + Aprepitant (80mg) for 2 days."

Trial Locations (1)

54000

Prof. Dr. Riffat Mehboob, Lahore

All Listed Sponsors

lead

Lahore Medical Research Center, LLP

INDUSTRY

NCT06317064 - Diagnostic and Therapeutic Potential of Substance P/ NK1R Receptor in Primary Dysmenorrhea | Biotech Hunter | Biotech Hunter